Evidence map›Paper›PMID 24086319›Full record

ArticlePloS one2013

Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants.

Scott Dryden-Peterson, Oluwemimo Jayeoba, Michael D Hughes, Haruna Jibril, Kenneth McIntosh, Taolo A Modise, Aida Asmelash, Kathleen M Powis, Max Essex, Roger L Shapiro and 1 more

3 registry-linked trialsOpen access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00197587 nacompletednot on this map

Prevention of Milk-Borne Transmission of HIV-1C in Botswana ("Mashi")

TypeinterventionalSponsorHarvard School of Public Health (HSPH)Ran2002Enrolled1,200ConditionsHIV Infection, Infant Risk for HIV Infection by MTCTArmsNevirapine, No intervention
NCT00270296 phase2completednot on this map

Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2006 to 2010Enrolled730ConditionsHIV InfectionsArmsTrizivir, Lamivudine/Zidovudine, Lopinavir/Ritonavir, Nevirapine
NCT01086878 phase4completednot on this map

Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana

TypeinterventionalSponsorHarvard School of Public Health (HSPH)Ran2009 to 2010Enrolled222ConditionsAcquired Immunodeficiency Syndrome, Infant, Newborn, Anemia, NeutropeniaArmscotrimoxazole
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Scott Dryden-PetersonDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America ; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana ; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Oluwemimo Jayeoba
Michael D Hughes
Haruna Jibril
Kenneth McIntosh
Taolo A Modise
Aida Asmelash
Kathleen M Powis
Max Essex
Roger L Shapiro
Shahin Lockman
Botswana Harvard AIDS Institute Partnership · BWHarvard University · USBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USMinistry of Health · BW

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Daniel Lingwood · 2004 to 2026
$94.4M
Fogarty International Clinical Research Scholars Support Center @ Vanderbilt-AAMCR24TW007988 · FIC · VANDERBILT UNIVERSITY · PI VERMUND, STEN H. · 2007 to 2011
$27.6M
Growth Trends and Mortality Risks Among HIV-exposed Infants in BotswanaK23HD070774 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI POWIS, KATHLEEN · 2012 to 2016
$686k
Risk factors for early morbidity and mortality of HIV-exposed uninfected infantsK23AI091434 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI DRYDEN-PETERSON, SCOTT · 2012 to 2016
$659k
FIC NIH HHS R24 TW007988NIAID NIH HHS K23 AI091434NIAID NIH HHS P30 AI060354NICHD NIH HHS K23 HD070774
6 · The paper itself

Abstract

backgroundProphylactic cotrimoxazole is recommended for infants born to HIV-infected mothers. However, cotrimoxazole may increase the risk of severe anemia or neutropenia.

methodsWe compared the proportion of HIV-exposed uninfected (HIV-EU) infants experiencing incident severe anemia (and separately, severe neutropenia) between a prospective cohort receiving prophylactic cotrimoxazole from 1 to 6 months vs. infants from two prior trials who did not receive cotrimoxazole. Infants were from rural and urban communities in southern Botswana.

resultsA total of 1705 HIV-EU infants were included. Among these 645 (37.8%) were fed with iron-supplemented formula from birth. Severe anemia developed in 87 (5.1%) infants, and severe neutropenia in 164 (9.6%) infants. In an analysis stratified by infant feeding method, there were no significant differences in the risk of severe anemia by prophylactic cotrimoxazole exposure-risk difference, -0.69% (95% confidence interval [CI] -2.1 to 0.76%). Findings were similar in multivariable analysis, adjusted odds ratio (aOR) 0.35 (95% CI 0.07 to 1.65). There were also no significant differences observed for severe neutropenia by cotrimoxazole exposure, risk difference 2.0% (95% CI -1.3 to 5.2%) and aOR 0.80 (95% CI 0.33 to 1.93).

conclusionsSevere anemia and severe neutropenia were infrequent among HIV-exposed uninfected infants receiving cotrimoxazole from 1-6 months of age. Concerns regarding hematologic toxicity should not limit the use of prophylactic cotrimoxazole in HIV-exposed uninfected infants. CLINICALTRIAL.SGOV REGISTRATION NUMBERS: NCT01086878 (http://clinicaltrials.gov/show/NCT01086878), NCT00197587 (http://clinicaltrials.gov/show/NCT00197587), and NCT00270296 (http://clinicaltrials.gov/show/NCT00270296).

Indexed as

AnemiaAnti-Infective AgentsAntiretroviral Therapy, Highly ActiveHIV InfectionsHumansInfantNeutropeniaProspective StudiesTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Infective AgentsTrimethoprim, Sulfamethoxazole Drug Combination

Identifiers

PMID24086319
PMCPMC3781096
OpenAlexW2107628746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.